Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. 1987

J E Egan, and J L Weber, and W R Ballou, and M R Hollingdale, and W R Majarian, and D M Gordon, and W L Maloy, and S L Hoffman, and R A Wirtz, and I Schneider

As part of a study of potential vaccines against malaria, the protective efficacy of sporozoite subunit vaccines was determined by using the Plasmodium berghei murine malaria model. Mice were immunized with recombinant DNA-produced or synthetic peptide-carrier subunit vaccines derived from the repetitive epitopes of the Plasmodium berghei circumsporozoite gene, or with radiation-attenuated sporozoites. Immunization with subunit vaccines elicited humoral responses that were equivalent to or greater than those elicited by irradiated sporozoites, yet the protection against sporozoite challenge induced by either of the subunit vaccines was far less than that achieved by immunization with attenuated sporozoites. Passive and adoptive transfer studies demonstrated that subunit vaccines elicited predominantly antibody-mediated protection that was easily overcome whereas irradiated sporozoites induced potent cell-mediated immunity that protected against high challenge doses of sporozoites. These studies indicate that new strategies designed to induce cellular immunity will be required for efficacious sporozoite vaccines.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D008288 Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. Marsh Fever,Plasmodium Infections,Remittent Fever,Infections, Plasmodium,Paludism,Fever, Marsh,Fever, Remittent,Infection, Plasmodium,Plasmodium Infection
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D010962 Plasmodium berghei A protozoan parasite of rodents transmitted by the mosquito Anopheles dureni. Plasmodium bergheus,berghei, Plasmodium
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000953 Antigens, Protozoan Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered. Protozoan Antigens
D000954 Antigens, Surface Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated. Cell Surface Antigens,Surface Antigens,Surface Markers, Immunological,Cell Surface Antigen,Immunologic Surface Markers,Markers, Immunological Surface,Surface Antigen,Surface Markers, Immunologic,Antigen, Cell Surface,Antigen, Surface,Antigens, Cell Surface,Immunological Surface Markers,Markers, Immunologic Surface,Surface Antigen, Cell,Surface Antigens, Cell

Related Publications

J E Egan, and J L Weber, and W R Ballou, and M R Hollingdale, and W R Majarian, and D M Gordon, and W L Maloy, and S L Hoffman, and R A Wirtz, and I Schneider
January 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene,
J E Egan, and J L Weber, and W R Ballou, and M R Hollingdale, and W R Majarian, and D M Gordon, and W L Maloy, and S L Hoffman, and R A Wirtz, and I Schneider
January 2017, Expert review of vaccines,
J E Egan, and J L Weber, and W R Ballou, and M R Hollingdale, and W R Majarian, and D M Gordon, and W L Maloy, and S L Hoffman, and R A Wirtz, and I Schneider
July 1986, The American journal of tropical medicine and hygiene,
J E Egan, and J L Weber, and W R Ballou, and M R Hollingdale, and W R Majarian, and D M Gordon, and W L Maloy, and S L Hoffman, and R A Wirtz, and I Schneider
April 1987, Microbial pathogenesis,
J E Egan, and J L Weber, and W R Ballou, and M R Hollingdale, and W R Majarian, and D M Gordon, and W L Maloy, and S L Hoffman, and R A Wirtz, and I Schneider
January 2018, Frontiers in immunology,
J E Egan, and J L Weber, and W R Ballou, and M R Hollingdale, and W R Majarian, and D M Gordon, and W L Maloy, and S L Hoffman, and R A Wirtz, and I Schneider
September 1990, Seminars in immunology,
J E Egan, and J L Weber, and W R Ballou, and M R Hollingdale, and W R Majarian, and D M Gordon, and W L Maloy, and S L Hoffman, and R A Wirtz, and I Schneider
January 1989, Advances in immunology,
J E Egan, and J L Weber, and W R Ballou, and M R Hollingdale, and W R Majarian, and D M Gordon, and W L Maloy, and S L Hoffman, and R A Wirtz, and I Schneider
December 1988, Biochemical Society transactions,
J E Egan, and J L Weber, and W R Ballou, and M R Hollingdale, and W R Majarian, and D M Gordon, and W L Maloy, and S L Hoffman, and R A Wirtz, and I Schneider
September 1988, The Southeast Asian journal of tropical medicine and public health,
J E Egan, and J L Weber, and W R Ballou, and M R Hollingdale, and W R Majarian, and D M Gordon, and W L Maloy, and S L Hoffman, and R A Wirtz, and I Schneider
January 1985, Advances in experimental medicine and biology,
Copied contents to your clipboard!